Immediate skin responses can serve as clinical endpoints for needle-free jet injector treatments.

Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not been clearly defined. 

Now, a new study establishes immediate skin responses as clinical endpoints for needle-free jet injector treatments.

“In this ex vivo human skin study, we concluded that the immediate skin papule and residual fluid on the skin surface are relevant clinical endpoints for spring- and air-powered needle-free jet injector systems,” says study author Liora Bik, MD, a medical doctor and PhD candidate at the dermatology department at Erasmus University Medical Center in Rotterdam, the Netherlands, in a news release. “These endpoints are indispensable for the successful and safe treatment with needle-free jet injector systems in clinical practice.”

The preclinical report is published in Lasers in Surgery and Medicine (LSM).